Endothelinrezeptor-Antagonisten in der Therapie der pulmonalen arteriellen Hypertonie

Schlüsselwörter

pulmonale arterielle Hypertonie - Endothelinrezeptor-Antagonisten

Keywords

pulmonary arterial hypertension - endothelin-receptor antagonist

Literatur

• 1 Benza R l, Barst R J, Galie N. et al . Sitaxsentan for the treatment of pulmonary arterial hypertension: a 1-year, prospective, open-label observation of outcome and survival.  Chest. 2008;  134 775-782
• 2 DiCarlo V S, Chen S J, Meng Q C. et al . ETA-receptor antagonist prevents and reverses chronic hypoxia-induced pulmonary hypertension in rat.  Am J Physiol. 1995;  269 (5 Pt1) 1690-1697
• 3 Givertz M M, Colucci W S, LeJemtel T H. et al . Acute endothelin A receptor blockade causes selective pulmonary vasodilation in patients with chronic heart failure.  Circulation. 2000;  101 2922-2927
• 4 Hiramoto Y, Shioyama W, Kuroda T. et al . Effect of bosentan on plasma endothelin-1 concentration in patients with pulmonary arterial hypertension.  Circ J. 2007;  71 367-369
• 5 Kiowski W, Sütsch G, Hunziker P. et al . Evidence for endothelin-1-mediated vasoconstriction in severe chronic heart failure.  Lancet. 1995;  346 732-736
• 6 Rubens C, Ewert R, Halank M. et al . Big endothelin-1 and endothelin-1 plasma levels are correlated with the severity of primary pulmonary hypertension.  Chest. 2001;  120 1562-1569
• 7 Sütsch G, Kiowski W, Yan X W. et al . Short-term oral endothelin-receptor antagonist therapy in conventionally treated patients with symptomatic severe chronic heart failure.  Circulation. 1998;  98 2262-2268
• 8 Williamson D J, Wallman L L, Jones R. et al . Hemodynamic effects of Bosentan, an endothelin receptor antagonist, in patients with pulmonary hypertension.  Circulation. 2000;  102 411-418